Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LURASIDONE vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

LURASIDONE vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN: Safety Overview

Metric LURASIDONE LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Total FAERS Reports 17,232 10,716
Deaths Reported 709 1,461
Death Rate 4.1% 13.6%
Hospitalizations 2,381 545
Average Patient Age 40.7 yrs 72.9 yrs
% Female Patients 68.2% 0.7%
FDA Approval Date Apr 26, 2012 Mar 23, 2022
Manufacturer Ascend Laboratories, LLC Novartis Pharmaceuticals Corporation
Route ORAL INTRAVENOUS
Marketing Status Prescription Prescription